Drug intelligence / Profile preview

IDP-107

Development stage: Unknown
Lead developer: Dow
Modality: Small Molecules
Administration: Oral

Overview

IDP-107 is an oral small molecule antibiotic that was developed for the treatment of moderate to severe acne vulgaris. The drug was originally developed by Dow Pharmaceutical Sciences, which later became part of Ortho Dermatologics and Bausch Health. Clinical development included phase 2 trials evaluating its safety and efficacy in patients with acne vulgaris. The precise mechanism of action has not been publicly disclosed, but as an oral antibiotic for acne, it is presumed to act against skin-associated bacteria implicated in the pathogenesis of acne[1][2][3][4][5].

Beyond the preview

Go deeper on IDP-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDP-107.

Explore the full profile